{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Vaidya Sane Ayurved Laboratories Ltd
Vaidya Sane Ayurved Laboratories Ltd is Rated Hold
Vaidya Sane Ayurved Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 27 January 2026, providing investors with an up-to-date view of the company’s performance and outlook.
Why is Vaidya Sane Ayurved Laboratories Ltd falling/rising?
On 09-Jan, Vaidya Sane Ayurved Laboratories Ltd experienced a notable decline in its share price, falling by 3.4% to ₹259.95 as of 09:08 PM. This drop comes amid broader short-term underperformance despite the company’s impressive long-term growth trajectory and market-beating returns over the past year.
Vaidya Sane Ayurved Laboratories Ltd is Rated Hold
Vaidya Sane Ayurved Laboratories Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 03 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 January 2026, providing investors with the latest insights into its performance and outlook.
Vaidya Sane Ayurved Laboratories Ltd is Rated Hold
Vaidya Sane Ayurved Laboratories Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 03 June 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of its performance and prospects.
Vaidya Sane Sees Revision in Market Evaluation Amid Mixed Financial Signals
Vaidya Sane, a microcap player in the hospital sector, has experienced a revision in its market evaluation reflecting nuanced shifts across key analytical parameters. This adjustment comes amid a backdrop of strong year-to-date returns and a complex financial and technical profile, prompting investors to reassess the stock’s positioning within its sector.
Is Vaidya Sane overvalued or undervalued?
As of November 6, 2025, Vaidya Sane is considered very expensive and overvalued with a PE ratio of 48.20 and an EV to EBITDA of 26.00, significantly higher than its peers like Sun Pharma and Cipla, despite a strong year-to-date return of 90.47%.
How has been the historical performance of Vaidya Sane?
Vaidya Sane has shown significant growth from Mar'22 to Mar'25, with net sales rising to 89.85 Cr despite a decline from the previous year, and profit before tax increasing to 9.90 Cr. The company improved its operating profit and earnings per share, indicating a strong upward trend in revenue and profitability.
Why is Vaidya Sane falling/rising?
As of 29-Oct, Vaidya Sane Ayurved Laboratories Ltd is seeing a price increase to 274.95, with a 1.08% rise and strong performance metrics, including a year-to-date increase of 98.45%. The stock is outperforming the benchmark Sensex and has experienced significant investor interest, reflected in a 61.76% rise in delivery volume.
Vaidya Sane Ayurved Laboratories Ltd Surges 3.85% Today, Up 94.88% Year-to-Date
Vaidya Sane Ayurved Laboratories Ltd is experiencing notable buying interest, with a significant rise in its stock price today. Over the past week, month, and year, the company has outperformed the Sensex, reflecting strong momentum and positive sentiment in the microcap hospital sector.
Vaidya Sane Ayurved Laboratories Stock Hits Upper Circuit at Rs 273.0, Up 5%
Vaidya Sane Ayurved Laboratories Ltd, a microcap in the hospital sector, saw significant trading activity today, reaching its upper circuit limit. The stock outperformed its sector and the Sensex, with notable trading volume and turnover. Despite a drop in delivery volume, liquidity remains adequate, indicating positive market sentiment.
Why is Vaidya Sane falling/rising?
As of 15-Oct, Vaidya Sane Ayurved Laboratories Ltd's stock price is declining at 259.10, down 4.04%, and has underperformed its sector today. Despite a strong long-term performance with a year-to-date return of +87.01%, recent trends indicate challenges in maintaining momentum against broader market gains.
Is Vaidya Sane overvalued or undervalued?
As of October 10, 2025, Vaidya Sane is considered overvalued with a valuation grade of expensive, reflected by a PE ratio of 49.32 and high EV to EBITDA ratio of 26.37, especially when compared to peers like Sun Pharma and Cipla, despite a strong year-to-date stock return of 94.88%.
Is Vaidya Sane overvalued or undervalued?
As of October 10, 2025, Vaidya Sane is considered overvalued with a PE ratio of 49.32, significantly higher than its peers like Sun Pharma and Cipla, despite impressive year-to-date returns of 94.88%.
Is Vaidya Sane overvalued or undervalued?
As of October 10, 2025, Vaidya Sane is considered overvalued with a valuation grade of expensive, reflected by a high PE ratio of 49.32 compared to peers like Sun Pharma and Cipla, despite impressive year-to-date returns of 94.88%.
Vaidya Sane Ayurved Laboratories Faces Selling Pressure with 5.05% Weekly Loss Amid Market Gains
Vaidya Sane Ayurved Laboratories Ltd is experiencing notable selling pressure, continuing a trend of losses over recent days. Despite a strong performance in the past three months and a significant yearly increase, the stock's recent decline contrasts with the positive movement of the Sensex. Long-term performance shows a divergence from broader market growth.
Vaidya Sane Ayurved Laboratories Ltd Hits Lower Circuit Limit at Rs 272.4
Vaidya Sane Ayurved Laboratories Ltd faced notable trading activity today, with its stock hitting the lower circuit limit. The stock's performance was below the sector average, showing limited price movement and increased investor participation, despite a challenging market environment characterized by a significant drop.
Vaidya Sane Ayurved Laboratories Ltd Faces 4.99% Decline Amid Significant Selling Pressure Today
Vaidya Sane Ayurved Laboratories Ltd is experiencing notable selling pressure, with a decline of 4.99% today, continuing a downward trend over the past week and month. Despite a strong performance earlier this year, recent market sentiment has shifted, leading to challenges for the stock's position.
Is Vaidya Sane overvalued or undervalued?
As of October 7, 2025, Vaidya Sane is considered very expensive with a PE ratio of 52.37 and significantly higher valuation metrics compared to peers like Sun Pharma and Cipla, indicating it may be overvalued despite a strong year-to-date return of 106.93%.
Is Vaidya Sane overvalued or undervalued?
As of October 6, 2025, Vaidya Sane is considered overvalued with a valuation grade of expensive, reflected by a high PE ratio of 50.05 and significant premiums compared to peers like Sun Pharma and Cipla, despite a strong year-to-date return of 97.76%.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
